RU2017145521A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017145521A3 RU2017145521A3 RU2017145521A RU2017145521A RU2017145521A3 RU 2017145521 A3 RU2017145521 A3 RU 2017145521A3 RU 2017145521 A RU2017145521 A RU 2017145521A RU 2017145521 A RU2017145521 A RU 2017145521A RU 2017145521 A3 RU2017145521 A3 RU 2017145521A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0082132 | 2015-06-10 | ||
| KR20150082132 | 2015-06-10 | ||
| KRPCT/KR2015/005917 | 2015-06-12 | ||
| PCT/KR2015/005917 WO2016199964A1 (ko) | 2015-06-10 | 2015-06-12 | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 |
| PCT/KR2016/006215 WO2016200220A1 (ko) | 2015-06-10 | 2016-06-10 | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017145521A RU2017145521A (ru) | 2019-07-11 |
| RU2017145521A3 true RU2017145521A3 (ru) | 2019-07-17 |
| RU2705899C2 RU2705899C2 (ru) | 2019-11-12 |
Family
ID=57504160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017145521A RU2705899C2 (ru) | 2015-06-10 | 2016-06-10 | Антитело, специфично связывающееся с изолированным пептидом, образованным из виментина, или связывающийся с этим пептидом фрагмент |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10961300B2 (ru) |
| EP (1) | EP3309169A4 (ru) |
| JP (1) | JP6720298B2 (ru) |
| KR (1) | KR101912375B1 (ru) |
| CN (2) | CN114605529A (ru) |
| AU (2) | AU2016277027B2 (ru) |
| CA (1) | CA2988715C (ru) |
| RU (1) | RU2705899C2 (ru) |
| WO (1) | WO2016199964A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018162724A1 (en) * | 2017-03-09 | 2018-09-13 | Mab Discovery Gmbh | Antibodies specifically binding to human il-1r7 |
| WO2019045182A1 (ko) * | 2017-08-31 | 2019-03-07 | 주식회사 이뮨메드 | 비멘틴 유래 펩타이드에 특이적으로 결합하는 물질을 포함하는 피부질환 예방 및 치료용 조성물 |
| CN108998423A (zh) * | 2018-09-03 | 2018-12-14 | 无锡傲锐东源生物科技有限公司 | 抗波形蛋白(Vimentin)单克隆抗体及其用途 |
| KR20230031015A (ko) * | 2021-08-26 | 2023-03-07 | 주식회사 이뮨메드 | 자가면역질환의 예방 또는 치료를 위한 항체의약품 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020006660A1 (en) * | 1996-03-01 | 2002-01-17 | Rhone-Poulenc Rorer, S.A. | Genetically-modified neural progenitors and uses thereof |
| JP3829226B2 (ja) * | 1999-07-07 | 2006-10-04 | 独立行政法人理化学研究所 | ビメンチンの切断産物に対する抗体 |
| KR100425030B1 (ko) | 2002-02-01 | 2004-03-27 | 주식회사 이뮨메드 | 신규한 항바이러스 ｖｓｆ 단백질 및 이를 분비하는하이브리도마 |
| US7691582B2 (en) | 2002-09-27 | 2010-04-06 | The Regents Of The University Of Michigan | Methods of secretory vimentin detection and modulation |
| JP2004168691A (ja) * | 2002-11-19 | 2004-06-17 | Yoshihide Hagiwara | 癌細胞増殖抑制ヒトモノクローナル抗体の取得法 |
| US7670604B2 (en) * | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| JP2007515924A (ja) * | 2003-12-15 | 2007-06-21 | アウレリウム バイオファーマ インク． | ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法 |
| WO2006053061A2 (en) * | 2004-11-10 | 2006-05-18 | Kansas State University Research Foundation | Porcine reproductive and respiratory syndrome virus receptor components and uses thereof |
| DE102005029845B4 (de) * | 2005-06-27 | 2017-03-23 | Orgentec Diagnostika Gmbh | Verfahren zur Diagnose von rheumatischen Erkrankungen |
| CA2651800A1 (en) | 2006-04-24 | 2007-11-08 | Shantha West, Inc. | Agrm2 antigen |
| CU23896B1 (es) * | 2010-04-01 | 2013-05-31 | Ct De Ingeniería Genética Y Biotecnología | Método para inhibir la replicación del vih en células de mamíferos |
| US20130274125A1 (en) * | 2012-04-16 | 2013-10-17 | Bio-Rad Laboratories Inc. | Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases |
| RU2523413C1 (ru) * | 2012-12-14 | 2014-07-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) | СПОСОБ ДИАГНОСТИКИ РЕВМАТОИДНОГО АРТИРИТА ПО НАЛИЧИЮ АНТИТЕЛ К МОДИФИЦИРОВАННОМУ ЦИНТРУЛЛИНИРОВАННОМУ ВИМЕНТИНУ (Anti-MCV) В РОТОВОЙ ЖИДКОСТИ |
| CN105209489B (zh) * | 2013-03-05 | 2019-06-14 | 得克萨斯州大学系统董事会 | 针对间质和上皮-间质转化的循环肿瘤细胞的特异性检测工具 |
| EP2784510A1 (en) * | 2013-03-25 | 2014-10-01 | Universität Zu Köln | Methods of diagnosing and differentiating oncocytoma and malignant renal carcinoma as well as products and uses relating thereto |
| US20160159922A1 (en) * | 2013-07-24 | 2016-06-09 | Vilara Ab | Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis |
-
2015
- 2015-06-12 WO PCT/KR2015/005917 patent/WO2016199964A1/ko active Application Filing
-
2016
- 2016-06-10 CA CA2988715A patent/CA2988715C/en active Active
- 2016-06-10 CN CN202210259412.1A patent/CN114605529A/zh active Pending
- 2016-06-10 EP EP16807860.8A patent/EP3309169A4/en active Pending
- 2016-06-10 RU RU2017145521A patent/RU2705899C2/ru active
- 2016-06-10 KR KR1020160072697A patent/KR101912375B1/ko active IP Right Grant
- 2016-06-10 AU AU2016277027A patent/AU2016277027B2/en active Active
- 2016-06-10 JP JP2018517109A patent/JP6720298B2/ja active Active
- 2016-06-10 US US15/570,734 patent/US10961300B2/en active Active
- 2016-06-10 CN CN201680034171.3A patent/CN108026167B/zh active Active
-
2019
- 2019-06-28 AU AU2019204638A patent/AU2019204638A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2988715A1 (en) | 2016-12-15 |
| CN114605529A (zh) | 2022-06-10 |
| US20190256585A1 (en) | 2019-08-22 |
| EP3309169A1 (en) | 2018-04-18 |
| WO2016199964A1 (ko) | 2016-12-15 |
| RU2017145521A (ru) | 2019-07-11 |
| AU2019204638A1 (en) | 2019-07-18 |
| CA2988715C (en) | 2022-11-22 |
| EP3309169A4 (en) | 2019-01-02 |
| KR20160146579A (ko) | 2016-12-21 |
| CN108026167B (zh) | 2022-04-05 |
| AU2016277027B2 (en) | 2019-07-18 |
| KR101912375B1 (ko) | 2018-10-29 |
| US10961300B2 (en) | 2021-03-30 |
| RU2705899C2 (ru) | 2019-11-12 |
| CN108026167A (zh) | 2018-05-11 |
| JP6720298B2 (ja) | 2020-07-08 |
| AU2016277027A1 (en) | 2017-12-21 |
| JP2018522582A (ja) | 2018-08-16 |